Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, nearly 90% of analysts who cover the stock have assigned a Buy or equivalent rating. The consensus 1-year median price target of $73 implies a 76% upside.

Earlier, on January 28, Vera Therapeutics Inc. (NASDAQ:VERA) appointed Matt Skelton as Chief Commercial Officer, who previously served as the executive vice president of the company’s commercial department.

Meanwhile, on January 27, JPMorgan reiterated its Overweight rating and $96 price target on Vera Therapeutics Inc. (NASDAQ:VERA), noting that as competitive readouts emerge in the space, the company’s shares could gradually move higher toward a more appropriate probability-adjusted level. The firm also thinks that atacicept, Vera’s lead drug candidate, is well-positioned in the IgA nephropathy (IgAN) B-Cell modulator space.

On January 16, Cantor Fitzgerald maintained its Overweight rating and $100 price target on the company, expressing confidence in the company’s regulatory prospects and commercial preparations. According to the analyst, all the pieces are in place for a successful regulatory outcome for atacicept’s potential approval for treating IgA nephropathy.

Vera Therapeutics Inc. (NASDAQ:VERA) is a clinical-stage biotech company developing and commercializing transformative treatments for immunological diseases.

While we acknowledge the potential of VERA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Best High-Upside Materials Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.